Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Haematopoietic Stem Cell Transplantation

Trial Profile

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Haematopoietic Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Antithrombin III (Primary)
  • Indications Thrombosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 26 Apr 2017 Planned primary completion date changed from 1 May 2016 to 1 Dec 2017.
    • 17 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top